APA

Van Lümig P. P. M., Lecluse L. L. A., Driessen R. J. B., Spuls P. I., Boezeman J. B., van de Kerkhof P. C. M. & De Jong E. M. G. J. (20110308). Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. : The British journal of dermatology.

Chicago

Van Lümig P P M, Lecluse L L A, Driessen R J B, Spuls P I, Boezeman J B, van de Kerkhof P C M and De Jong E M G J. 20110308. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. : The British journal of dermatology.

Harvard

Van Lümig P. P. M., Lecluse L. L. A., Driessen R. J. B., Spuls P. I., Boezeman J. B., van de Kerkhof P. C. M. and De Jong E. M. G. J. (20110308). Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. : The British journal of dermatology.

MLA

Van Lümig P P M, Lecluse L L A, Driessen R J B, Spuls P I, Boezeman J B, van de Kerkhof P C M and De Jong E M G J. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. : The British journal of dermatology. 20110308.